Medical treatment for diabetic retinopathy: Do the FIELD microvascular study results support a role for lipid lowering?

Practical Diabetes International

Volumn 25, Issue 2, 2008, Pages 76-79

  Dodson, Paul M ^a,b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Diabetic retinopathy; Fibrates; FIELD study; Lipids; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEVACIZUMAB; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; OCTREOTIDE; PEGAPTANIB; PLACEBO; ROSUVASTATIN; RUBOXISTAURIN; SIMVASTATIN; VASCULOTROPIN INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; HUMAN; LIPID BLOOD LEVEL; LOW LEVEL LASER THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RHABDOMYOLYSIS; RISK FACTOR;

EID: 54849428973     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.1210     Document Type: Review

References (34)

1. Fong DS, Aiello LP, Ferris FL, et al. Diabetic retinopathy. Diabetes Care 2004; 27: 2540-2553.
2. Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multiethnic cohort in the United States. Am J Ophthalmol 2006; 141: 446-455.
3. Knudsen LL, Lervang HH, Lundbye-Christensen S, et al. The North Jutland County Diabetic Retinopathy Study: population characteristics. Br J Ophthalmol 2006; 90: 1404-1409.
4. Diabetes UK. Diabetes and blindness: a focus on action. A report from Diabetes UK. June 2005. Available from http://www.diabetes.org.uk
5. Day C. The rising tide of type 2 diabetes. Br J Diabetes Vasc Dis 2001; 1: 37-43.
6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
7. Donaldson M, Dodson PM. Medical treatment of diabetic retinopathy. Eye 2003; 17: 550-562.
8. Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350: 48-58.
9. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 2005; 6: 511-524.
10. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-969.
11. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmol 1991; 98: 766-785.
12. Cunningham ET, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmol 2005; 112: 1747-1757.
13. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006; 26: 1006-1013.
14. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe non-proliferative diabetic retinopathy. Initial results of the protein kinase C beta inhibitor retinopathy study (PKC-DRS) multicenter randomised clinical trial. Diabetes 2005; 54: 2188-2197.
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
16. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
17. Stratton IM, Cull CA, Adler AI, et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2005; 49: 1761-1769.
18. Dodson PM, Galton DJ, Winder AF. Retinal vascular abnormalities in the hyperlipidemias. Trans Ophthalmol Soc UK 1981; 101: 17-21.
19. Chew EY, Klein ML, Ferris FL, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. ETDRS Report 22. Arch Ophthalmol 1996; 114: 1079-1084.
20. Chowdhury TA, Hopkins D, Dodson PM, et al. The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid-lowering therapy? Eye 2002; 16: 689-693.
21. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910-918.
22. Ucgun NI, Yildirim Z, Kilic N, et al. The importance of serum lipids in exudative diabetic macular edema in type 2 diabetic patients. Ann NY Acad Sci 2007; 100: 213-217.
23. Duncan LJ, Cullen JF, Ireland JT, et al. A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes 1968; 17: 458-467.
24. Harrold BP, Marmion VJ, Gough KR. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 1969; 18: 285-291.
25. Cullen JF, Town SM, Campbell CJ. Double-blind trial of Atromid-S in exudative diabetic retinopathy. Trans Ophthalmol Soc UK 1974; 94: 554-562.
26. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
27. Chew EY, Ambrosius WT, Howard LT, et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am J Cardiol 2007; 99: 103i-111i.
28. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
29. Keech AC, Mitchell P, Summanen PA, et al, for the FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370(9600): 1687-1697. Epub 2007 Nov 7.
30. Simó R, Hernández C. Fenofibrate for diabetic retinopathy. Lancet 2007; 370(9600): 1667-1668. Epub 2007 Nov 7.
31. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol 2001; 280: C1358-C1366.
32. Malik J, Melenovsky V, Wichterle D, et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc Res 2001; 52: 290-298.
33. Rosenson RS, Wolff DA, Huskin AL, et al. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 2007; 30: 1945-1951.
34. Kim J, Ahn JH, Kim JH, et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 2007; 84: 886-893.